DBV Technologies S.A. (NASDAQ:DBVT) Short Interest Update

DBV Technologies S.A. (NASDAQ:DBVT) saw a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 298,500 shares, an increase of 7.1% from the August 31st total of 278,800 shares. Based on an average daily volume of 48,300 shares, the days-to-cover ratio is presently 6.2 days. Currently, 0.3% of the shares of the company are short sold.

DBV Technologies Stock Up 2.8 %

Shares of NASDAQ:DBVT opened at $0.72 on Wednesday. The company has a market cap of $69.43 million, a P/E ratio of -0.86 and a beta of 0.68. DBV Technologies has a 52 week low of $0.50 and a 52 week high of $2.74. The company has a 50-day moving average price of $0.85 and a 200 day moving average price of $1.05.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. During the same quarter in the previous year, the business earned ($0.26) EPS. Analysts expect that DBV Technologies will post -1.43 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on DBVT. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price objective on shares of DBV Technologies in a report on Tuesday, September 24th. StockNews.com began coverage on DBV Technologies in a report on Friday, September 27th. They set a “hold” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of DBV Technologies in a report on Thursday, August 1st.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. increased its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the period. DBV Technologies accounts for about 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th biggest position. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.